http://www.reuters.com/article/2012/07/23/us-onyx-bayer-tarceva-idUSBRE86M0G020120723

认领翻译的战友请跟帖注明“认领本文翻译，48小时内未完成，请其他战友认领！”
请根据自己专业背景选择认领，如使用翻译软件翻译，被发现者扣分1-2分
请根据自己的专业背景选择相应的资讯认领，经常认领而不能及时提供优质稿件者将被列入黑名单，取消认领资格，请大家注意！
新近参与本次活动的会员请查看：动态版重启资讯翻译计划：我为人人，人人为我，共同提高 - 丁香园论坛
寻找最近的翻译贴请查看：http://search.dxy.cn/?words=%E8%B5%84%E8%AE%AF%E7%BF%BB%E8%AF%91&bid=116&t=1&c=1&age=7&bid=116&limit=30&o=1
翻译时请参照版规 科技动态版版规及加分细则（ 2014-02-21 更新） - 丁香园论坛
希望参与动态版其他活动的会员请查看版面右边栏的置顶部分

The combination of cancer tablets Tarceva and Nexavar to treat patients with liver cancer failed to improve overall survival rates compared with standard Nexavar treatment in a late-stage Phase III trial, drug companies involved said on Monday.

Analysts at brokerage Cheuvreux said the news was a small negative for Bayer AG , the lead partner in the trial, but they left peak sales forecasts for Nexavar unchanged at 971 million euros ($1.18 billion) in 2019.

Bayer and Onyx Pharmaceuticals Inc jointly produce Nexavar, while Tarceva -- which is used for treating lung cancer -- is sold by Astellas Pharma Inc and Genentech, a unit of Roche Holding AG.

The trial was conducted through a partnership of Bayer, Onyx, Astellas and Roche.

A Roche spokesman said that while the Swiss company provided financial support as well as Tarceva for the trial, it did not have a development plan for Tarceva as a liver cancer treatment, either alone or as part of a drug combination.

Details of the study, which enrolled 720 patients with hepatocellular carcinoma, the most common form of liver cancer, will be presented at a scientific meeting later.